Dental gel Cholisal at the stage of conservative treatment of inflammatory periodontal diseases

Close metadata

PURPOSE OF THE STUDY

To study the effectiveness of the drug Cholisal as part of the conservative treatment of chronic periodontitis.

MATERIAL AND METHODS

We selected 100 patients aged 35 to 65 years of both sexes with a diagnosis of moderate chronic periodontitis in the acute stage with a periodontal pocket depth of 3.5—5 mm. Depending on the tactics of conservative treatment of periodontitis, patients were divided into two groups of 50 people. In the main group, Cholisal dental gel was used as part of complex conservative treatment, and in the control group, Metrogil-denta gel was used. To assess the effectiveness of treatment, a dental examination of patients was carried out with an index assessment of the condition of periodontal tissues and a biochemical analysis of the content of arachidonic acid and prostaglandin E2 in gingival blood, comparing the indicators before treatment and 14 days after the start of treatment.

RESULTS

When the drug Cholisal was included in complex treatment, 14 days from the start of treatment, patients experienced a statistically significant decrease in the depth of periodontal pockets from 4.7±0.32 mm to 3.6±0.19, and the Green—Vermillion hygiene index by 60.7%, Silness—Loe plaque index by 73.1%, PMA index by 68.8%, Muhlemann—Cowell bleeding index by 68.0% (p<0.001 compared to baseline). When Metrogil-denta gel was used in complex therapy, the effectiveness of treatment was lower: the depth of periodontal pockets did not change significantly (from 4.5±0.22 mm to 4.2±0.17 mm, p>0.05), reduction in the hygiene index Green—Vermillion was 51.9%, Silness—Loe plaque index — 64.0%, PMA index — 43.7%, Muhlemann—Cowell bleeding index — 45.8% (p<0.001 compared to baseline, p<0.001 compared to the main group). A laboratory study showed that in patients of the main group, after completing a course of conservative treatment, the content of biomarkers of inflammation significantly decreased compared to the initial level (p<0.05), while in patients of the control group the content of arachidonic acid and prostaglandin E2 in the gingival blood during the study period did not change significantly (p>0.05 compared to the initial level).

CONCLUSIONS

The use of the drug Cholisal in the conservative treatment of chronic periodontitis has demonstrated more pronounced positive dynamics of clinical and biochemical parameters compared to traditional therapy, which suggests its high effectiveness.

Keywords:

chronic periodontitis

Cholisal

arachidonic acid

prostaglandin E2

high sensitivity C-reactive protein

reduction of periodontal indices

Authors:

Rabinovich I.M.

Central Research Institute of Dentistry and Maxillofacial Surgery

ORCID: 0000-0001-8539-814X

Snegirev M.V.

Central Research Institute of Dentistry and Maxillofacial Surgery of Ministry of Health of the Russian Federation

ORCID: 0000-0002-4758-2963

Petrukhina N.B.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0003-3840-8127

Boriskina O.A.

Russian University of Medicine of Ministry of Health of the Russian Federation

ORCID: 0000-0002-1649-6448

Saltovets M.V.

FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation

ORCID: 0000-0003-0673-2555

Received:

15.03.2024

Accepted:

01.04.2024

List of references:

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990±2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100): 1211-1259. https://doi.org/10.1016/S0140-6736(17)32154-2
Nazir M, Al-Ansari A, Al-Khalifa K, Alhareky M, Gaffar B, Almas K. Global Prevalence of Periodontal Disease and Lack of Its Surveillance. Sci World J. 2020;2020:2146160. https://doi.org/10.1155/2020/2146160
Van Dyke TE, Bartold PM, Reynolds EC. The Nexus Between Periodontal Inflammation and Dysbiosis. Front Immunol. 2020;11:511. https://doi.org/10.3389/fimmu.2020.00511
Chervinets VM, Chervinets YuV, Leont’eva AV, Kozlova EA, Stulov NM, Belyaev VS, Grigoryants EO, Mironov AYu. The microbiome of oral cavity patients with periodontitis, adhesive and biofilm forming properties. Klinicheskaya laboratornaya diagnostika. 2021;66(1):45-51. (In Russ.). https://doi.org/10.18821/0869-2084-2021-66-1-45-51
Sedghi LM, Bacino M, Kapila YL. Periodontal Disease: The Good, The Bad, and The Unknown. Front Cell Infect Microbiol. 2021;11:766944. https://doi.org/10.3389/fcimb.2021.766944
Hasturk H, Kantarci A. Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 2000. 2015;69(1):255-273. https://doi.org/10.1111/prd.12105
Zorina OA, Antidze MK, Aĭmadinova NK, Muranova IN. The content of phosphoinositides and their metabolites in blood components in patients with chronic generalized periodontitis. Stomatologiia (Mosk). 2012;91(5): 11-13. (In Russ.).
Cafiero C, Spagnuolo G, Marenzi G, Martuscelli R, Colamaio M, Leuci S. Predictive periodontitis: the Most promising salivary biomarkers for early diagnosis of periodontitis. J Clin Med. 2021;10:1488. https://doi.org/10.3390/jcm10071488
Chen J, Du Y, Zhou XD, Zhang P. Salivary Metabolic Profiling in Patients with Periodontitis. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53(5):842-850. https://doi.org/10.12182/20220960207
Huang Y, Zhu M, Li Z, Sa R, Chu Q, Zhang Q, Zhang H, Tang W, Zhang M, Yin H. Mass spectrometry-based metabolomic profiling identifies alterations in salivary redox status and fatty acid metabolism in response to inflammation and oxidative stress in periodontal disease. Free Radic Biol Med. 2014; 70:223-232. https://doi.org/10.1016/j.freeradbiomed.2014.02.024
Orekhova LYu, Loboda ES, Atrushkevich VG, Kosova EV, Vashneva VYu, Petrov AA. Relevance of non-steroidal anti-inflammatory drugs in periodontology. Parodontologiya. 2021;26(3):211-222. (In Russ.). https://doi.org/10.33925/1683-3759-2021-26-3-211-222
Isola G, Tartaglia GM, Santonocito S, Chaurasia A, Marya A, Lo Giudice A. Growth differentiation factor-15 and circulating biomarkers as predictors of periodontal treatment effects in patients with periodontitis: a randomized-controlled clinical trial. BMC Oral Health. 2023;23(1):582. https://doi.org/10.1186/s12903-023-03237-y
Machado V, Botelho J, Escalda C, Hussain SB, Luthra S, Mascarenhas P, Orlandi M, Mendes JJ, D’Aiuto F. Serum C-Reactive Protein and Periodontitis: A Systematic Review and Meta-Analysis. Front Immunol. 2021;12: 706432. eCollection 2021. https://doi.org/10.3389/fimmu.2021.706432
Fischer RG, Gomes Filho IS, Cruz SSD, Oliveira VB, Lira-Junior R, Scannapieco FA, Rego RO. What is the future of Periodontal Medicine? Braz Oral Res. 2021;35(suppl 2):e102. https://doi.org/10.1590/1807-3107bor-2021.vol35.0102
Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018; 89(suppl S1):S173-S182. https://doi.org/10.1002/JPER.17-0721
Alvarez Echazú MI, Olivetti CE, Anesini C, Perez CJ, Alvarez GS, Desimone MF. Development and evaluation of thymol-chitosan hydrogels with antimicrobial-antioxidant activity for oral local delivery. Mater Sci Eng C Mater Biol Appl. 2017;81:588-596. https://doi.org/10.1016/j.msec.2017.08.059
Zhao H, Hu J, Zhao L. Adjunctive subgingival application of Chlorhexidine gel in nonsurgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis. BMC Oral Health. 2020;20(1):34. https://doi.org/10.1186/s12903-020-1021-0
Bescos R, Ashworth A, Cutler C, Brookes ZL, Belfield L, Rodiles A, Casas-Agustench P, Farnham G, Liddle L, Burleigh M, White D, Easton C, Hickson M. Effects of Chlorhexidine mouthwash on the oral microbiome. Sci Rep. 2020;10(1):5254. https://doi.org/10.1038/s41598-020-61912-4
Brookes ZLS, Bescos R, Belfield LA, Ali K, Roberts A. Current uses of chlorhexidine for management of oral disease: a narrative review. J Dent. 2020; 103:103497. https://doi.org/10.1016/j.jdent.2020.103497
Lee JH. Injectable hydrogels delivering therapeutic agents for disease treatment and tissue engineering. Biomater Res. 2018;22(1):27. https://doi.org/10.1186/s40824-018-0138-6
Velichko EV, Vasil’ev YuL. Eculiarities of selection of modern adhesive medications for treatment of inflammatory periodontal and oral mucosa diseases. Klinicheskaya stomatologiya. 2022;25(4):64-72. (In Russ.). https://doi.org/10.37988/1811-153X_2022_4_64
Aleksandrov MT, Prikuls VF, Bogdanov VIu, Vasil’ev EN. Antimicrobial activity determination of the preparations used in comprehensive treatment of patients with parodontitis. Stomatologiia (Mosk). 2009;88(2):13-15. (In Russ.).
Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Can Fam Physician. 2020; 66:651-659.
Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. Periodontol. 2016;71:82-112. https://doi.org/10.1111/prd.12121
Matesanz-Pérez P, García-Gargallo M, Figuero E, Bascones-Martínez A, Sanz M, Herrera D. A systematic review on the effects of local antimicrobials as adjuncts to subgingival debridement, compared with subgingival debridement alone, in the treatment of chronic periodontitis. J Clin Periodontol. 2013;40:227-241. https://doi.org/10.1111/jcpe.12026
Herrera D, Sanz M, Kebschull M, Jepsen S, Sculean A, Berglundh T, Papapanou PN, Chapple I, Tonetti MS. Treatment of stage IV periodontitis: the EFP S3 level clinical practice guideline. J Clin Periodontol. 2022; 49(S24):4-71. https://doi.org/10.1111/jcpe.13639
Maksimova OP. The role of the drug «Cholisal» in complex treatment of periodontal disease and oral mucosa. Klinicheskaya stomatologiya. 2018;2(86): 46-49. (In Russ.). https://doi.org/10.37988/1811-153X_2018_2_46
Krikheli NI, Pustovoit EV, Darsigova ZT. The effectiveness of the drug Cholisal in the complex treatment of oral mucosa and periodontal diseases. Stomatologiia. 2022;101(6):98-102. (In Russ.). https://doi.org/10.17116/stomat202210106198
Malan’in IV, Popova IK. Evaluation of the effectiveness of the drug Cholisal in the complex treatment of periodontal diseases. Mezhdunarodnyj zhurnal prikladnyh i fundamental’nyh issledovanij. 2013;6:71-72. (In Russ.).
Rabinovich IM, Petrukhina NB, Shikh EV, Polyakov VM, Sandler IV. Dental gel Cholisal at the stage of conservative treatment of inflammatory periodontal diseases. Stomatologiya. 2023;102(5):34-39. (In Russ.). https://doi.org/10.17116/stomat202310205134
Hartung JE, Eskew O, Wong T, Tchivileva IE, Oladosu FA, O’Buckley SC, Nackley AG. Nuclear factor-kappa B regulates pain and COMT expression in a rodent model of inflammation. Brain Behav Immun. 2015;50:196-202. https://doi.org/10.1016/j.bbi.2015.07.014
Kotowska-Rodziewicz A, Zalewska A, Maciejczyk M. A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drugs in Dentistry. Med Sci Monit. 2023;29:e940635. https://doi.org/10.12659/MSM.940635
Lingappan K. NF-κB in oxidative stress. Curr Opin Toxicol. 2018;7:81-86. https://doi.org/10.1016/j.cotox.2017.11.002
Yao C, Narumiya S. Prostaglandin-cytokine crosstalk in chronic inflammation. Br J Pharmacol. 2019;176(3):337-354. https://doi.org/10.1111/bph.14530
Liljestrand JM, Paju S, Pietiainen M, Buhlin K, Persson GR, Nieminen MS, Sinisalo J, Mantyla P, Pussinen PJ. Immunologic burden links periodontitis to acute coronary syndrome. Atherosclerosis. 2018;268:177-184. https://doi.org/10.1016/j.atherosclerosis.2017.12.007

Close metadata